As Vice President and Head of Medical Affairs at Gamida Cell since 2021, Smitha Sivaraman established the Medical Affairs organization from the ground up, developing and executing strategies that led to the successful launch of Gamida Cell’s first FDA-approved cell therapy. Smitha is a strategic partner with clinical development and R&D for the development of research collaborations and Phase 1 studies, as well as pipeline assets. She also drives the publication strategy and cross-functional collaboration with the commercial and market access teams for Gamida Cell. Smitha is a valued medical expert for corporate communications, strategic partnership negotiations and payer group discussions. Smitha previously worked at Incyte Corporation for 10 years, where she gained commercial launch expertise with the FDA approvals of Ruxolitinib and Pemigatinib. Smitha has a Ph.D. in Biochemistry from the University of Bombay, Mumbai, India and an M.B.A. in Pharmaceutical and Healthcare Marketing from St. Joseph’s University.